Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-APOC3 in hypertriglyceridemia and familial chylomicronemia syndrome
NCT03783377Phase 1Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Feb 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 1, randomised trial in hypertriglyceridemia and familial chylomicronemia syndrome (FCS) comparing ARO-APOC3 with Placebo (2 arms). Primary endpoint: Adverse Events Possibly or Probably Related to Treatment at 113 days. Started Mar 2019; status: completed.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemiafamilial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT03783377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783377.